MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease

Phase 4
Completed
Conditions
Asthma
COPD
Interventions
First Posted Date
2007-02-26
Last Posted Date
2020-03-27
Lead Sponsor
University of Saskatchewan
Target Recruit Count
28
Registration Number
NCT00440245
Locations
🇨🇦

University of Saskatchewan, Saskatoon, Saskatchewan, Canada

A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control

Phase 4
Conditions
Asthma
First Posted Date
2006-10-09
Last Posted Date
2006-10-09
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
10
Registration Number
NCT00385359
Locations
🇨🇦

Toronto Western Hospital - Respiratory Research Lab, Toronto, Ontario, Canada

A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2006-10-05
Last Posted Date
2017-02-01
Lead Sponsor
AstraZeneca
Target Recruit Count
1080
Registration Number
NCT00384189
Locations
🇺🇦

Altana Pharma/Nycomed, Zaporizhzhya, Ukraine

As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma

Phase 3
Completed
Conditions
Asthma
First Posted Date
2006-10-02
Last Posted Date
2020-08-03
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
480
Registration Number
NCT00382889
Locations
🇵🇱

Clinic of Infection Diseases and Allergology - Central Clinical Hospital of Military Medical Academy, Warszawa, Poland

🇦🇹

Pulmologisches Zentrum Der Stadt Wien, Wien, Austria

🇵🇱

Specialist Group Medex, Bielsko Biala, Poland

and more 22 locations

Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2006-07-31
Last Posted Date
2016-10-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
54
Registration Number
NCT00358488
Locations
🇬🇧

GSK Investigational Site, Manchester, United Kingdom

Bronchodilators and Oxygen Kinetics With Exercise in Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 4
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
First Posted Date
2006-07-20
Last Posted Date
2011-04-19
Lead Sponsor
Queen's University
Target Recruit Count
12
Registration Number
NCT00354354
Locations
🇨🇦

Respiratory Investigation Unit (Queen's University), Kingston, Ontario, Canada

Viapaed Study In Children And Adolescents With Asthma

Phase 4
Completed
Conditions
Asthma
Interventions
First Posted Date
2006-04-19
Last Posted Date
2017-10-19
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
285
Registration Number
NCT00315744
Locations
🇩🇪

GSK Investigational Site, Hamburg, Germany

The Effect of Nebulized Albuterol on Donor Oxygenation

Phase 2
Completed
Conditions
Brain Death
Organ Donor
Pulmonary Edema
Interventions
Drug: Albuterol
Drug: Saline
First Posted Date
2006-04-03
Last Posted Date
2018-03-16
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
506
Registration Number
NCT00310401
Locations
🇺🇸

California Transplant Donor Network, Oakland, California, United States

Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Placebo
Drug: Albuterol
First Posted Date
2006-03-30
Last Posted Date
2022-04-01
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
95
Registration Number
NCT00308685
Locations
🇺🇸

Allergy & Asthma Specialist Medical Group, Huntington Beach, California, United States

🇺🇸

Little Rock Allergy and Asthma, Little Rock, Arkansas, United States

🇺🇸

Allergy & Asthma Associates of Santa Clara Valley Research Center, San Jose, California, United States

and more 9 locations

Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations

Phase 4
Completed
Conditions
Asthma
First Posted Date
2006-01-09
Last Posted Date
2011-06-01
Lead Sponsor
AstraZeneca
Target Recruit Count
20
Registration Number
NCT00272753
Locations
🇳🇱

Research Site, Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath